Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes

Author(s):
Reichardt, P.; Demetri, G.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.G.; Mehren, M. von; Schoffski, P.; Blackstein, M.E.; Cesne, A. le; Badalamenti, G.; Xu, J.; Nishida, T.; Kuss, I.; Casali, P.G.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-10-31
Language
English
Is part of
Onkologie (2013), Vol. 36, p. 179-180
hdl
1887/102620